Cargando…

Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists

BACKGROUND AND AIMS: The recognition of transarterial chemoembolization (TACE) failure/refractoriness among Chinese clinicians remains unclear. Using an online survey conducted by the Chinese College of Interventionalists (CCI), the aim of this study was to explore the recognition of TACE failure/re...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Bin-Yan, Wang, Wan-Sheng, Zhang, Shen, Zhu, Hai-Dong, Zhang, Lei, Shen, Jian, Zhu, Xiao-Li, Teng, Gao-Jun, Ni, Cai-Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369015/
https://www.ncbi.nlm.nih.gov/pubmed/34447681
http://dx.doi.org/10.14218/JCTH.2021.00049
_version_ 1783739201772060672
author Zhong, Bin-Yan
Wang, Wan-Sheng
Zhang, Shen
Zhu, Hai-Dong
Zhang, Lei
Shen, Jian
Zhu, Xiao-Li
Teng, Gao-Jun
Ni, Cai-Fang
author_facet Zhong, Bin-Yan
Wang, Wan-Sheng
Zhang, Shen
Zhu, Hai-Dong
Zhang, Lei
Shen, Jian
Zhu, Xiao-Li
Teng, Gao-Jun
Ni, Cai-Fang
author_sort Zhong, Bin-Yan
collection PubMed
description BACKGROUND AND AIMS: The recognition of transarterial chemoembolization (TACE) failure/refractoriness among Chinese clinicians remains unclear. Using an online survey conducted by the Chinese College of Interventionalists (CCI), the aim of this study was to explore the recognition of TACE failure/refractoriness and review TACE application for hepatocellular carcinoma (HCC) treatment in clinical practice. METHODS: From 27 August 2020 to 30 August 2020 during the CCI 2020 annual meeting, a survey with 34 questions was sent by email to 264 CCI clinicians in China with more than 10 years of experience using TACE for HCC treatment. RESULTS: A total of 257 clinicians participated and responded to the survey. Most participants agreed that the concept of “TACE failure/refractoriness” has scientific and clinical significance (n=191, 74.3%). Nearly half of these participants chose TACE-based combination treatment as subsequent therapy after so-called TACE failure/refractoriness (n=88, 46.1%). None of the existing TACE failure/refractoriness definitions were widely accepted by the participants; thus, it is necessary to re-define this concept for the treatment of HCC in China (n=235, 91.4%). Most participants agreed that continuing TACE should be performed for patients with preserved liver function, presenting portal vein tumor thrombosis (n=242, 94.2%) or extrahepatic spread (n=253, 98.4%), after the previous TACE treatment to control intrahepatic lesion(s). CONCLUSIONS: There is an obvious difference in the recognition of TACE failure/refractoriness among Chinese clinicians based on existing definitions. Further work should be carried out to re-define TACE failure/refractoriness.
format Online
Article
Text
id pubmed-8369015
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher XIA & HE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-83690152021-08-25 Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists Zhong, Bin-Yan Wang, Wan-Sheng Zhang, Shen Zhu, Hai-Dong Zhang, Lei Shen, Jian Zhu, Xiao-Li Teng, Gao-Jun Ni, Cai-Fang J Clin Transl Hepatol Original Article BACKGROUND AND AIMS: The recognition of transarterial chemoembolization (TACE) failure/refractoriness among Chinese clinicians remains unclear. Using an online survey conducted by the Chinese College of Interventionalists (CCI), the aim of this study was to explore the recognition of TACE failure/refractoriness and review TACE application for hepatocellular carcinoma (HCC) treatment in clinical practice. METHODS: From 27 August 2020 to 30 August 2020 during the CCI 2020 annual meeting, a survey with 34 questions was sent by email to 264 CCI clinicians in China with more than 10 years of experience using TACE for HCC treatment. RESULTS: A total of 257 clinicians participated and responded to the survey. Most participants agreed that the concept of “TACE failure/refractoriness” has scientific and clinical significance (n=191, 74.3%). Nearly half of these participants chose TACE-based combination treatment as subsequent therapy after so-called TACE failure/refractoriness (n=88, 46.1%). None of the existing TACE failure/refractoriness definitions were widely accepted by the participants; thus, it is necessary to re-define this concept for the treatment of HCC in China (n=235, 91.4%). Most participants agreed that continuing TACE should be performed for patients with preserved liver function, presenting portal vein tumor thrombosis (n=242, 94.2%) or extrahepatic spread (n=253, 98.4%), after the previous TACE treatment to control intrahepatic lesion(s). CONCLUSIONS: There is an obvious difference in the recognition of TACE failure/refractoriness among Chinese clinicians based on existing definitions. Further work should be carried out to re-define TACE failure/refractoriness. XIA & HE Publishing Inc. 2021-08-28 2021-04-08 /pmc/articles/PMC8369015/ /pubmed/34447681 http://dx.doi.org/10.14218/JCTH.2021.00049 Text en © 2021 Authors. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Zhong, Bin-Yan
Wang, Wan-Sheng
Zhang, Shen
Zhu, Hai-Dong
Zhang, Lei
Shen, Jian
Zhu, Xiao-Li
Teng, Gao-Jun
Ni, Cai-Fang
Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists
title Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists
title_full Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists
title_fullStr Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists
title_full_unstemmed Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists
title_short Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists
title_sort re-evaluating transarterial chemoembolization failure/refractoriness: a survey by chinese college of interventionalists
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369015/
https://www.ncbi.nlm.nih.gov/pubmed/34447681
http://dx.doi.org/10.14218/JCTH.2021.00049
work_keys_str_mv AT zhongbinyan reevaluatingtransarterialchemoembolizationfailurerefractorinessasurveybychinesecollegeofinterventionalists
AT wangwansheng reevaluatingtransarterialchemoembolizationfailurerefractorinessasurveybychinesecollegeofinterventionalists
AT zhangshen reevaluatingtransarterialchemoembolizationfailurerefractorinessasurveybychinesecollegeofinterventionalists
AT zhuhaidong reevaluatingtransarterialchemoembolizationfailurerefractorinessasurveybychinesecollegeofinterventionalists
AT zhanglei reevaluatingtransarterialchemoembolizationfailurerefractorinessasurveybychinesecollegeofinterventionalists
AT shenjian reevaluatingtransarterialchemoembolizationfailurerefractorinessasurveybychinesecollegeofinterventionalists
AT zhuxiaoli reevaluatingtransarterialchemoembolizationfailurerefractorinessasurveybychinesecollegeofinterventionalists
AT tenggaojun reevaluatingtransarterialchemoembolizationfailurerefractorinessasurveybychinesecollegeofinterventionalists
AT nicaifang reevaluatingtransarterialchemoembolizationfailurerefractorinessasurveybychinesecollegeofinterventionalists